Beyond specific angiogenesis inhibitors, approved compounds such as antiandrogens, PARP inhibitors and PSMA-targeting approaches probably also have a substantial anti-angiogenic impact in PCa biology. The gene discussed is FOLH1; the disease is posterior cortical atrophy.